Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Procedure: 5 cm colon-J-pouch
Procedure: side-to-end anastomosis
Procedure: straight coloanal anastomosis

First Posted Date: 2005-10-13

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 336

Registration Number: NCT00238381

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇩🇪
Kreiskrankenhaus Lörrach, Lörrach, Germany
🇨🇭
Inselspital Bern, Bern, Switzerland

and more 15 locations

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-10-06

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Registration Number: NCT00234026

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Spital Uster, Uster, Switzerland
🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland

and more 10 locations

Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine and oxaliplatin
Drug: capecitabine and oxaliplatin + cetuximab

First Posted Date: 2005-09-28

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 74

Registration Number: NCT00227734

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇨🇭
Saint Claraspital AG, Basel, Switzerland

and more 15 locations

Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab

First Posted Date: 2005-09-28

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 270

Registration Number: NCT00227695

Locations: 🇧🇷
Clinical Center - Institute of Hematology, Sao Paulo, Brazil
🇮🇹
Istituto Europeo di Oncologia IEO, Milano, Italy
🇿🇦
Panorama Medical Centre, Cape Town, South Africa

and more 23 locations

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine
Drug: irinotecan hydrochloride
Drug: oxaliplatin

First Posted Date: 2005-09-22

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 23

Registration Number: NCT00217711

Locations: 🇨🇭
Hirslanden Klinik Aarau, Lausanne, Switzerland
🇨🇭
City Hospital Triemli, Zurich, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland

and more 1 locations

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 63

Registration Number: NCT00217698

Locations: 🇨🇭
Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭
Klinik Hirslanden, Zurich, Switzerland

and more 11 locations

Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-08-05

Last Posted Date: 2019-06-26

Lead Sponsor: Swiss Group for Clinical Cancer Research

Registration Number: NCT00004187

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland

Drugs to Reduce the Side Effects of Chemotherapy

Phase 3

Completed

Conditions: Nausea and Vomiting
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: dexamethasone
Drug: granisetron hydrochloride
Drug: metoclopramide hydrochloride

First Posted Date: 2004-08-02

Last Posted Date: 2012-07-11

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 267

Registration Number: NCT00003213

Locations: 🇨🇭
Istituto Oncologico della Svizzera Italiana, Lugano, Switzerland
🇨🇭
Burgerspital, Solothurn, Solothurn, Switzerland
🇮🇹
Istituto Europeo Di Oncologia, Milano, Italy

and more 7 locations

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-08-02

Last Posted Date: 2019-06-26

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 40

Registration Number: NCT00003259

Locations: 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana, Lugano, Switzerland

and more 7 locations

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-08-02

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 300

Registration Number: NCT00003214

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Klinik Hirslanden, Zurich, Switzerland
🇨🇭
City Hospital Triemli, Zurich, Switzerland

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy